An observational study in Hemorrhagic Stroke, Intracerebral, Subarachnoid Haemorrhage (SAH) and Postanoxic Coma, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Observational
The goal of this observational study is to develop and validate artificial intelligence (AI) algorithms that use subhairline EEG (a simplified EEG patch placed on the forehead and behind the ears) to predict neurological outcome and to detect intracranial hemorrhage. The study consists of two use cases: (UC1) adults (18 years or older) in postanoxic coma after cardiac arrest who are admitted to the intensive care unit (ICU), and UC2) adults with suspected stroke or suspected subarachnoid hemorrhage (SAH) who present to the emergency department. The primary objectives are:
Participants will:
In a final pilot phase, up to 10 patients per setting will be measured with the AI algorithms built into the EEG recording device, to evaluate feasibility and user-friendliness. In all phases, EEG and algorithm results are not used for clinical decisions.
**RATIONALE**
Electroencephalography (EEG) is a noninvasive tool for detecting and monitoring neuronal activity. It plays a crucial role in predicting neurological outcome in postanoxic coma after cardiac arrest (CA). It is also promising for prehospital detection of intracranial hemorrhage (ICrH), including intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH).
Conventional scalp EEG has two practical limitations. Its electrodes must be carefully placed on the scalp by specialized personnel. Its interpretation requires expertise, is time-consuming and is prone to interrater variability.
In critical care and emergency settings, time is critical and specialist availability is often limited. In acute stroke care, rapid detection of ICrH is essential to start early appropriate treatment. In postanoxic coma after CA, early EEG monitoring after ICU admission is recommended to accurately predict neurological outcome.
Recent pilot studies suggest that subhairline EEG is a reliable and easy alternative to scalp EEG for these time-critical settings. Subhairline EEG is a simplified configuration consisting of a single patch applied on the forehead and behind the ears. In addition, artificial intelligence (AI) algorithms for automated interpretation of subhairline EEG could provide rapid and reliable decision support in both settings.
**HYPOTHESIS**
The investigators hypothesize that AI algorithms based on subhairline EEG can accurately predict neurological outcome in patients with postanoxic coma after CA. The investigators also hypothesize that such algorithms can accurately detect ICH in patients with suspected stroke.
**OBJECTIVE**
**STUDY DESIGN**
This is an investigator-initiated, monocenter, observational study at Amsterdam UMC. It consists of three steps.
Step 1: Algorithm development. Several EEG-based AI algorithms will be developed and pre-trained using existing scalp EEG data and clinical data (UC1: >900 patients, UC2: >1000 patients).
Step 2: Prospective data collection. Subhairline EEG data and clinical data will be collected with the TrianecT subhairline EEG recording device. Sample sizes are based on 10-20 events per predictor.
Step 3: Algorithm fine-tuning, validation and feasibility. The pre-trained algorithms will be fine-tuned and validated on the collected subhairline EEG data using transfer learning. The algorithms will then be integrated into the TrianecT software (SMART-EEG). Practical and clinical feasibility will be evaluated in up to 10 patients per use case. This evaluation is not intended for CE certification.
**STUDY POPULATION**
All participants are 18 years or older.
**INTERVENTION**
All participants undergo a subhairline EEG recording with a single patch applied on the forehead and behind the ears.
**MAIN END POINTS**
Primary end points:
Secondary end points:
221 studies on the registry are indexed under Hemorrhagic Stroke; 86 are open to participants now.
This study's planned enrollment of 825 is above the median of 300 across 66 observational studies indexed under Hemorrhagic Stroke.
Browse Hemorrhagic Stroke studies →Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 532 studies on the registry; 185 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults (18 years or older) in three cohorts at Amsterdam UMC: patients in postanoxic coma after cardiac arrest admitted to the intensive care unit, patients with suspected or confirmed stroke presenting to the emergency department, and patients with suspected or confirmed subarachnoid hemorrhage presenting to the emergency department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants:
- Age 18 years or older
Postanoxic coma (ICU):
Suspected stroke (emergency department):
Suspected subarachnoid hemorrhage (emergency department):
Exclusion Criteria:
All participants:
- (Suspected) skin damage or infection at the placement area of the subhairline EEG patch
Postanoxic coma (ICU):
- Other types of severe brain injury, either pre-existing or coinciding with cardiac arrest. These include stroke, traumatic brain injury and progressive neurodegenerative disease.
adults in postanoxic coma after cardiac arrest admitted to the ICU
adults with suspected or confirmed stroke presenting to the emergency department
adults with suspected or confirmed subarachnoid hemorrhage presenting to the emergency department
Prognostic performance of a subhairline EEG-based AI algorithm for neurological outcome prediction in postanoxic coma
Performance of the AI algorithm, based on subhairline EEG recorded at 24 hours after cardiac arrest, in predicting poor neurological outcome. Poor outcome is defined as CPC 3-5 at hospital discharge. Performance is expressed as the area under the ROC curve (AUC), sensitivity, specificity, positive and negative predictive values, each with 95% confidence intervals. The optimal cut-off for poor outcome is defined as the highest sensitivity at a false positive rate of 0%.
Time frame: EEG at 24 hours after cardiac arrest; neurological outcome at hospital discharge (up to 3 months after CA)
Diagnostic accuracy of a subhairline EEG-based AI algorithm for detection of intracerebral hemorrhage
Diagnostic accuracy of the AI algorithm, based on subhairline EEG and clinical symptoms, in detecting intracerebral hemorrhage (ICH) in patients with suspected stroke. The reference standard is the final diagnosis based on neuroimaging. Accuracy is expressed as the area under the ROC curve (AUC), and as sensitivity, specificity, positive and negative predictive values at the optimal cut-off, each with 95% confidence intervals.
Time frame: EEG at presentation (within 24 hours of symptom onset); final diagnosis at hospital discharge (up to 3 months after presentation)
Prognostic performance of subhairline EEG-based AI algorithms for neurological outcome prediction at hourly intervals between 6 and 24 hours after cardiac arrest
Performance of AI algorithms, based on subhairline EEG recorded at each hour between 6 and 24 hours after cardiac arrest, in predicting poor neurological outcome. Poor outcome is defined as CPC 3-5 at hospital discharge. Performance is expressed as AUC, sensitivity, specificity, positive and negative predictive values, each with 95% confidence intervals. The cut-off is defined as the highest sensitivity at a false positive rate of 0%.
Time frame: EEG at each hour from 6 to 24 hours after cardiac arrest; neurological outcome at hospital discharge (up to 3 months after CA)
Diagnostic accuracy of a subhairline EEG-based AI algorithm for detection of subarachnoid hemorrhage
Diagnostic accuracy of the AI algorithm, based on subhairline EEG and clinical symptoms, in detecting subarachnoid hemorrhage (SAH) in patients with suspected SAH. Accuracy is expressed as AUC, and as sensitivity, specificity, positive and negative predictive values at the optimal cut-off, each with 95% confidence intervals.
Time frame: EEG at presentation (within 48 hours of symptom onset); final diagnosis at hospital discharge (up to 3 months after presentation)
Feasibility of SMART-EEG in the intensive care unit
Practical and clinical feasibility of the subhairline EEG device with integrated AI algorithms (SMART-EEG) in up to 10 postanoxic coma patients in the ICU. Feasibility includes user-friendliness as rated by users . Algorithm results are not used for clinical decisions.
Time frame: During the recording, from ICU admission up to 72 hours after cardiac arrest
Feasibility of SMART-EEG in the in-hospital acute stroke setting
Practical and clinical feasibility of SMART-EEG in up to 10 patients with suspected stroke in the emergency department. Feasibility includes user-friendliness as rated by users. Algorithm results are not used for clinical decisions.
Time frame: At the time of the EEG recording, at presentation (Day 1)
Plan to share: No — Individual participant data will not be made publicly available, due to privacy regulations (GDPR) and the consent procedures used in this study. Pseudonymized data may be shared with collaborating parties, including the device manufacturer, only under a data sharing agreement and only for participants who gave consent or did not object to such sharing.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 42 observational studies under Hemorrhagic Stroke, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 15. This study's planned 24 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →